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1  | INTRODUCTION
Molecular targeted strategies using specific targets in cancer cells 
have been widely used in the field of drug discovery,1,2 drug deliv‐
ery,3 drug administration4 and diagnosis.5,6 The application of these 
treatment strategies has resulted in good outcomes in terms of can‐
cer diagnosis and treatment. However, there are still many difficul‐
ties in the development of novel cancer targets that show acceptable 
efficacy. It is, therefore, necessary to identify novel and potentially 
effective cancer targets and targeting strategies.
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Abstract
Cancer‐specific antigens expressed in the cell membrane have been used as targets 
for several molecular targeted strategies in the last 20 years with remarkable success. 
To develop more effective cancer treatments, novel targets and strategies for tar‐
geted therapies are needed. Here, we examined the cancer cell membrane‐resident 
“cis‐bimolecular complex” as a possible cancer target (cis‐bimolecular cancer target: 
BiCAT)	using	proximity	proteomics,	a	technique	that	has	attracted	attention	in	the	
last	 10	 years.	BiCAT	were	detected	using	 a	 previously	 developed	method	 termed	
the	enzyme-mediated	activation	of	radical	source	(EMARS),	to	label	the	components	
proximal	to	a	given	cell	membrane	molecule.	EMARS	analysis	identified	some	BiCAT,	
such	as	close	homolog	of	L1	(CHL1),	fibroblast	growth	factor	3	(FGFR3)	and	α2 inte‐
grin, which are commonly expressed in mouse primary lung cancer cells and human 
lung	squamous	cell	carcinoma	cells.	Analysis	of	cancer	specimens	from	55	lung	can‐
cer	patients	revealed	that	CHL1	and	α2 integrin were highly co–expressed in almost 
all	cancer	tissues	compared	with	normal	 lung	tissues.	As	an	example	of	BiCAT	ap‐
plication, in vitro simulation of effective drug combinations used for multiple drug 
treatment	 strategies	was	 performed	 using	 reagents	 targeted	 to	BiCAT	molecules.	
The	 combination	 treatment	 based	 on	 BiCAT	 information	 moderately	 suppressed	
cancer cell proliferation compared with single administration, suggesting that the in‐
formation	about	BiCAT	in	cancer	cells	is	useful	for	the	appropriate	selection	of	the	
combination	among	molecular	targeted	reagents.	Thus,	BiCAT	has	the	potential	 to	
contribute to several molecular targeted strategies in future.
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Many molecular targeted strategies have been developed against 
cell	 surface	 (membrane)	 proteins	 such	 as	 receptor	 tyrosine	 kinases	
(RTK),	 which	 are	 involved	 in	 cell	 proliferation	 and	 differentiation.	
Previous	 studies	 have	 shown	 that	 cell	 surface	 (membrane)	 proteins	
non–randomly form a heterocomplex accompanied by the fluidity of 
biological membranes.7 In particular, regions in the membrane with 
high concentration of specific molecular complexes together with spe‐
cific lipids are “lipid rafts.” These lipid rafts in the cellular membrane 
serve as a platform for intracellular signaling and are also involved in 
various biological phenomena.7 In addition, research in drug discovery 
and treatment against several diseases has focused on lipid rafts.3,8,9 
Thus, it is essential to identify the molecules that form cis‐molecular 
complexes in the cell membrane, especially cancer cell‐specific com‐
plexes, with the aim of applying these findings to targeted strategies.
Proximity	proteomics10‐13 has recently been used as a method 
to	analyze	molecular	complexes.	We	developed	a	simple	and	phys‐
iological method, called the enzyme‐mediated activation of radical 
source	 (EMARS)	 method,14	 which	 uses	 HRP-induced	 radicals	 de‐
rived from arylazide or tyramide compounds.15	The	EMARS	radicals	
attack and form covalent bonds with the proteins in the proximity of 
the	HRP	(eg,	radicals	from	arylazide,	approximately	200-300	nm;14 
from tyramide, approximately 20 nm16)	because	the	generated	rad‐
icals immediately react with surrounding water molecules and dis‐
appear	when	near	HRP.	Therefore,	the	bimolecular	partner	proteins	
that interact and assemble with an overexpressed given membrane 
protein,	which	was	selected	based	on	cDNA	microarray	data,	could	
be labeled only with arylazide or tyramide compounds under phys‐
iological	 conditions	 (Figures	 1	 and	 S1).	 The	 labeled	 proteins	 can	
subsequently	be	analyzed	using	an	antibody	array	and/or	a	typical	
proteome strategy.17	The	EMARS	method	has	been	applied	in	vari‐
ous studies on molecular complexes on the cell membrane.18‐24
Here, we propose a “cis‐bimolecular complex”, a biostructure that 
contains 2 or more different membrane molecules associated with 
and/or located in close proximity to each other on the same cell mem‐
brane, as a new type of cancer target (cis‐bimolecular cancer target, 
hereinafter	referred	to	as	BiCAT)	that	was	identified	in	pursuit	of	diver‐
sifying	molecular	targeted	strategies.	We	used	the	EMARS	method	in	
Echinoderm Microtubule‐associated protein‐Like 4‐Anaplastic Lymphoma 
Kinase (EML4‐ALK)	transgenic	mouse	primary	lung	cancer	cells	(EML4‐
ALK	primary	cells)	and	LK2	human	lung	squamous	cell	carcinoma	cell	
line	 to	 identify	 several	 BiCAT.	 These	BiCAT	were	 also	 expressed	 in	
pathological specimens derived from lung cancer patients.
2  | MATERIALS AND METHODS
Part	of	the	“Materials	and	Methods”	are	in	Appendix	S1.
2.1 | Enzyme‐mediated activation of radical source 
reaction for cell membranes
The	 EMARS	 reaction	 and	 detection	 of	 EMARS	 products	 were	
performed as described previously.14 Briefly, EML4‐ALK primary 
cells,	 LK2	 cells,	 HEK293	 cells	 and	 CHL1	 transfectant	 HEK293	
cells	were	washed	once	with	PBS	at	room	temperature	and	then	
treated with either 5 μg/mL	of	HRP-conjugated	anti–mouse	CHL1	
antibody	 (AF2147;	 R&D	 systems)	 and	 anti–human	 CHL1	 anti‐
body	 (MAB2126;	 R&D	 systems)	 or	 4	 μg/mL	 of	 HRP-conjugated	
CTxB	 (LIST	Biological	 Laboratories)	 in	PBS	at	 room	 temperature	
for	 20	minutes.	 The	 cells	were	 then	 incubated	with	0.1	mmol/L	
fluorescein‐conjugated arylazide or fluorescein‐conjugated tyra‐
mide15 with 0.0075% H2O2	in	PBS	at	room	temperature	for	15	min‐
utes in the dark. The cell suspension was homogenized through a 
26 G syringe needle to break the plasma membranes, and samples 
were centrifuged at 20 000 g for 15 minutes to precipitate the 
plasma	membrane	fractions.	After	solubilization	with	NP-40	lysis	
buffer	(20	mmol/L	Tris-HCl	(pH	7.4),	150	mmol/L	NaCl,	5	mmol/L	
EDTA,	 1%	 NP-40,	 1%	 glycerol),	 the	 samples	 were	 subjected	 to	
SDS-PAGE	 (10%	gel,	under	non–reducing	conditions).	Gels	were	
blotted	 to	a	PVDF	membrane,	which	was	 then	blocked	with	5%	
skim milk solution. The membranes were then stained with goat 
anti–fluorescein antibody (Rockland; 0.2 μg/mL)	followed	by	HRP-
conjugated	anti–goat	IgG	(1:3000)	for	FT	detection.	Alternatively,	
for the direct detection of fluorescein‐labeled proteins in gel, gels 
after	electrophoresis	were	directly	subjected	to	a	ChemiDoc	MP	
Imaging	System	 (BIO-RAD)	equipped	with	 filters	 for	 fluorescein	
detection.
2.2 | Staining of pathological specimens from lung 
cancer patients
This	 study	 used	 a	 lung	 cancer	 patient	 tissue	 array	 (No.	 OD-CT-
RsLug04-003;	 Shanghai	 Outdo	 Biotech)	 that	 contains	 lung	 car‐
cinoma tissues and normal lung tissues derived from 55 lung 
cancer	 patients	 (30	 male	 and	 25	 female	 cases,	 mongoloid).25,26 
The specimens were deparaffinized with xylene and 70%‐100% 
ethanol.	 Antigen	 retrieval	 was	 carried	 out	 using	 L.A.B	 solution	
(Polysciences)	 at	 room	 temperature	 for	 10	 minutes.	 The	 slides	
were	then	gently	washed	with	PBS,	treated	with	5%	BSA-PBS	for	
30	 minutes	 and	 stained	 with	 anti–human	 CHL1	 antibody	 (4	 μg/
mL)	for	40	minutes	followed	by	Alexa	Fluor	546-conjugated	anti–
rat	IgG	(Thermo	Fisher	Scientific)	for	40	minutes.	After	the	CHL1	
staining,	 the	samples	were	subsequently	stained	with	anti–α2 in‐
tegrin	 antibody	 (Abcam;	 ab133557:	 4	 μg/mL),	 followed	 by	 Alexa	
Fluor	 488-conjugated	 anti–rabbit	 IgG	 (Thermo	 Fisher	 Scientific)	
for 40 minutes. The mounting media containing anti–fade reagent 
(DABCO;	Sigma-Aldrich)	and	DAPI	(Nacalai	Tesque)	was	incubated	
with specimens before observation. The samples were observed 
with	an	LSM	710	Laser	Scanning	Confocal	Microscope	(Carl	Zeiss)	
mounted	on	an	AxioImager	Z2	equipped	with	a	Diode,	argon	and	
He-Ne	laser	unit.	The	objective	lenses	were	EC-PLAN	NEOFLUAR	
5×/0.16	and	APOCHROMAT	20×/0.8.	Image	acquisition	and	analy‐
sis	was	carried	out	with	ZEN	2011	software	(Carl	Zeiss).	Raw	images	
including differential interference contrast images were captured 
under identical settings in the experiments and then exported to 
TIFF files.
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2.3 | In vitro proliferation inhibition assay
EML4‐ALK	primary	cells	and	LK2	cells	were	grown	on	96-well	culture	
plates (in the case of EML4‐ALK primary cells, the wells were coated 
with	 collagen	 I).	 After	 72	 hours,	 antibody	 and/or	 chemical	 inhibi‐
tors	against	CHL1,	FGFR3	α2	 integrin	and	EML4-ALK	were	added	
to	 medium	 as	 follows:	 anti–mouse	 CHL1	 antibody	 (AF2147;	 final	
concentration 2.5 μg/mL),	 anti–human	CHL1	antibody	 (MAB2126;	
final concentration 2.5 μg/mL),	FGFR	inhibitor	(PD173074;	Cayman	
Chemical;	 final	concentration	30	nmol/L),27 α2β1 integrin inhibitor 
(BTT3033;	R&D	systems;	final	concentration;	150	nmol/L)28,29 and 
ALK	 inhibitor	 (CH5424802;	 LKT	 Laboratories;	 final	 concentration;	
500	or	1000	nmol/L).30	Although	both	anti–CHL1	antibodies	bind	
to	 the	 extracellular	 domain	 of	 CHL1,	 the	 biological	 effects	 (ie,	 an	
inhibitory	 or	 activating	 effect	 for	 CHL1	 function)	 have	 not	 been	
reported. The final concentration of each reagent was determined 
based on previous reports22,27,29 and the data from the pilot studies 
(data	not	shown).	For	 the	 (IgG)2 antibody
31‐33 preparation, 4 types 
of antibody mix were prepared by simply mixing with cross‐linker 
antibody	as	2follows:	Ab	mix	1	 (anti–FGFR3	antibody	[Santa	Cruz;	
sc‐123]: 1 μg/mL	and	anti–rabbit	IgG	Fc	specific	antibody	[Jackson	
ImmunoResearch; 111‐005‐046]: 0.5 μg/mL);	 Ab	 mix	 2	 (anti–α2 
F I G U R E  1  Overview	of	BiCAT	analysis	for	cancer	cell	membrane.	Schematic	illustration	of	BiCAT	analysis.	Before	the	enzyme-mediated	
activation	of	radical	source	(EMARS)	method,	the	cancer	tissues	from	EML4‐ALK	transgenic	mice	were	applied	to	cDNA	microarray	analysis	
for	the	preparation	of	the	EMARS	probe,	and	primary	cell	inoculation	and	cultivation.	The	labeled	EMARS	products	were	analyzed	using	
mass spectrometry and/or antibody array
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integrin	antibody	[Abcam;	ab133557]:	1	μg/mL	and	anti–rabbit	IgG	
Fc specific antibody: 0.5 μg/mL);	Ab	mix	3	(anti–α2 integrin antibody: 
0.5 μg/mL,	anti–α2 integrin antibody: 0.5 μg/mL	and	anti–rabbit	IgG	
Fc specific antibody: 0.5 μg/mL);	 Ab	mix	 4	 (anti–α2 integrin anti‐
body: 0.5 μg/mL,	anti–α2 integrin antibody: 0.5 μg/mL).	These	Ab	
mixes were incubated at room temperature for 30 minutes to form 
(IgG)2	antibodies,	respectively	(Ab	mix	3	contains	FGFR3-α2 integ‐
rin-(IgG)2	antibody).	After	treatment,	short-term	culture	(3-5	days),	
additional treatment and cell counting were carried out according 
to	3	protocols:	 (a)	single	 treatment	and	cell	counting	at	Day	2	and	
Day	5;	(b)	daily	treatment	and	cell	counting	at	Day	2	and	Day	4;	(c)	
every‐other‐day treatment and cell counting at Day 1 and Day 3 with 
additional treatment at Day 2. Cell counting was performed using 
the	Cell	Counting	Kit-8	(Dojindo)	with	a	VarioSkan	Flash	microplate	
reader	(Thermo	Scientific)	at	450	nm.	Each	protocol	was	carried	out	
in	multiple	independent	experiments	(a:	n	=	6,	b:	n	=	5,	c:	n	=	4	[in	the	
case of EML4‐ALK	primary	cells:	n	=	3]).	In	the	case	of	(IgG)2 antibody 
administration,	protocol	(b)	was	carried	out	in	multiple	independent	
experiments	(n	=	4).
3  | RESULTS
3.1 | CHL1 is a suitable molecule for BiCAT analysis 
in EML4‐ALK transgenic mice
The	overall	scheme	of	BiCAT	analysis	for	cancer	cells	is	summarized	
in Figure 1. The first step is to identify the overexpressed molecules 
in	cancer	cell	membranes	by	cDNA	array	and	prepare	 the	EMARS	
probe.	 Next,	 EMARS	 is	 performed	 in	 (primary)	 cancer	 cells	 and	
tissues	 to	 identify	BiCAT	partner	molecules	 associated	with	 over‐
expressed	 molecules	 by	 proteome	 analysis.	 BiCAT	 information	 is	
possibly used for further applications (eg, the simulation of appro‐
priate drug combination for multi‐drug administration as described 
later	and	drug	design).
We	used	the	transgenic	mouse	of	the	onco-fusion	gene,	EML4‐
ALK,34,35 which causes spontaneously occurring lung cancer with 
early	onset,	since	it	is	suitable	for	biochemical	experiments.	We	first	
performed gene expression analysis in both lung tumor and normal 
tissues from EML4‐ALK	transgenic	mice	(Figure	2A)	by	whole	mouse	
cDNA	microarray	to	identify	highly	expressed	membrane	molecules	
in	lung	tumors	(Table	S1).	We	selected	4	genes	(Gjb4, MMP13, CHL1 
and Claudin 2)	that	were	overexpressed	in	lung	tumor	tissues	as	can‐
didate	membrane	proteins.	Reverse	transcription	PCR	revealed	that	
these genes were strongly expressed in lung cancer tumors com‐
pared	with	normal	tissue	(Figure	2B)	regardless	of	sex	and	age.	CHL1	
expression	was	detected	 in	 tumor	slices	 (Figure	2C)	and	 in	 lysates	
from	 lung	 tumors	 by	 western	 blot	 (Figure	 2D),	 but	 not	 in	 normal	
lung	tissue.	CHL1	was	reported	as	an	overexpressed	gene	in	human	
lung carcinoma tissue36	and	we	thus	selected	CHL1	for	subsequent	
analysis.
3.2 | Partner molecules constituting BiCAT 
with CHL1
We	next	used	primary	cancer	cells	derived	from	lung	cancer	tissue	
of EML4‐ALK	transgenic	mice	(Figure	3A)	 in	EMARS	reactions	with	
F I G U R E  2  CHL1	expression	in	lung	tumors	from	EML4‐ALK 
transgenic	mice.	A,	EML4‐ALK transgenic mouse lung cancers 
(Arrows).	Two	representative	tumor	formations	in	the	lung	(upper	
panel)	and	HE	staining	of	cancer	tissue	(lower	panel;	indicated	as	
the	dotted	area	of	“T”).	Scale	bar:	100	μm.	B,	RT-PCR	analyses	of	
Gjb4, MMP13, CHL1, Claudin2 and EML4‐ALK	mRNA	show	potent	
expression in lung cancer tissue. Tissues derived from 12 and 24‐wk 
old male and female mice were used for the analysis, respectively. 
N,	normal	tissue;	T,	tumor	tissue.	C,	Immunohistochemical	
staining of lung tissues from EML4‐ALK	transgenic	mouse.	CHL1	
staining	(upper	panel)	and	Claudin2	staining	(lower	panel)	were	
performed	using	anti–CHL1	and	anti–Claudin2	antibodies	with	DIC	
images. The dotted area indicates the tumor tissue (T).	D,	Protein	
expression	of	CHL1	in	cancer	tissue.	Tissue	lysate	from	lung	cancer	
tissue and normal tissue were subjected to western blot analysis 
using	mouse	CHL1	antibody.	N,	normal	tissue;	T,	tumor	tissue
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CHL1	probes	(Figure	S2).	The	CHL1	probes	used	in	this	study	were	
HRP-conjugated	 reduced	 antibodies	 recognizing	 the	 extracellular	
domain	of	human	and	mouse	CHL1.	HRP-conjugated	cholera	toxin	
subunit	B	(CTxB	probe),	which	is	the	cognitive	molecule	against	gan‐
glioside GM1 as a lipid raft marker,37 was used as a positive control. 
Using arylazide reagent, the CTxB probe sample generated strong 
signals;	 however,	moderate	 signals	were	 observed	with	 the	 CHL1	
probe	(Figure	3B).	Weak	non–specific	signals	were	observed	in	the	
negative	control	sample	obtained	by	EMARS	reaction	without	HRP-
conjugated	CHL1	probe.	In	contrast,	EMARS	reaction	using	tyramide	
F I G U R E  3  BiCAT	analysis	for	cultured	cancer	cells.	A,	Representative	image	of	EML4‐ALK	primary	cells.	B,	C,	Partner	molecules	with	
CHL1	in	EML4‐ALK	primary	cells	were	labeled	with	fluorescein-arylazide	(B)	and	fluorescein-tyramide	(C)	reagent.	Enzyme-mediated	
activation	of	radical	source	(EMARS)	products	were,	respectively,	subjected	to	western	blot	analysis	followed	by	staining	using	anti–
fluorescein	antibody.	“CTxB”	indicates	the	positive	control	sample	using	CTxB	probe,	“CHL1”	the	samples	using	CHL1	probe,	and	“(−)”	the	
negative	control	samples	(no	probe).	D,	EMARS	products	labeled	with	fluorescein-tyramide	in	LK2	cells.	Protein	expression	level	of	CHL1	
in	LK2	and	RERF	cells	(left	column).	EMARS	products	by	CTxB	and	human	CHL1	probes	(right	column).	Abbreviations	are	the	same	as	in	
(C).	E,	Human	receptor	tyrosine	kinase	(RTK)	antibody	array	analysis	of	EMARS	products	from	LK2	cells.	EMARS	samples	were	applied	to	
Human	RTK	antibody	array	according	to	the	manufacturer's	instructions.	“CHL1	probe	(+)”	indicates	the	sample	using	CHL1	probe,	and	
“CHL1	probe	(−)”	the	negative	control	samples	(no	probe).	The	proteins	corresponding	to	positive	RTK	were	indicated	in	the	array	data.	
F, Interaction between FGFR3 and α2	integrin	in	HEK293	cells.	HEK293	(mock)	and	CHL1	transfectant	(hCHL1)	cells	were	subjected	to	
western	blot	analysis	with	anti–CHL1	antibody	(left	panel).	The	EMARS	products	by	HRP-conjugated	anti	CHL1	antibody	from	HEK293	and	
CHL1	transfectant	cells	were	subjected	to	10%	SDS-PAGE	gel	followed	by	direct	fluorescein	detection	(middle	panel).	Immunoprecipitation	
experiment of fluorescein‐labeled α2	integrin	using	anti–fluorescein-Sepharose	(right	panel).	The	immunoprecipitation	samples	and	input	
lysate	were	subjected	to	6%	SDS-PAGE	gel	followed	by	the	western	blot	analysis	with	anti–α2 integrin antibody
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reagent	showed	clear	signals	 in	the	CHL1	probe	sample,	with	very	
faint	 signals	 in	 the	 negative	 control	 (Figure	 3C),	 suggesting	 that	
tyramide‐fluorescein reagent was suitable for this study in terms of 
specificity and sensitivity.
In	the	human	lung	carcinoma	cell	 lines,	CHL1	protein	was	ex‐
pressed	 in	 LK2	 cells	 but	 not	 in	 RERF	 cells	 (Figure	 3D).	 EMARS	
reaction	 in	LK2	cells	 indicated	 that	both	CTxB	and	human	CHL1	
probe sample contained fluorescein‐labeled proteins, indicated as 
the	partner	molecules	with	CHL1	but	not	 in	the	negative	control	
sample	(Figure	3D).	The	EMARS	products	were	subsequently	used	
for proteomic analysis with mass spectrometry. The identified 
membrane	 (-bound)	 proteins	 that	 are	 candidates	 for	 bimolecular	
partner	molecules	with	CHL1	are	summarized	in	Table	S2	(raw	data	
are	 in	Tables	S3-S6).	The	mass	spectrometry	analysis	 is	 the	main	
tool	for	BiCAT	analysis,	but	antibody	array	is	also	useful	 in	terms	
of its simplicity and sensitivity, especially for low expression mole‐
cules in protein lysates. The human RTK antibody array analysis for 
LK2	cells	demonstrated	that	EMARS	products	using	CHL1	probe	
contained	 some	RTK,	 especially	FGFR3	 (Figure	3E).	We	 selected	
6	 membrane	 (-bound)	 proteins,	 α2 integrin, β1 integrin, FGFR3, 
Na/K	 ATPase,	 clusterin	 and	 contactin1,	 as	 bimolecular	 partners	
with	CHL1.
By	using	HEK293	cells	 and	 its	human	CHL1	 transfectant	cells,	
the	 interaction	 between	 CHL1	 and	 α2 integrin in other cells was 
examined. HEK293 cells endogenously express α2 integrin, but 
not	CHL1	(Figure	3F,	Left panel).	We	performed	EMARS	reaction	in	
HEK293	cells	and	CHL1	transfectant	cells	with	HRP-labeled	human	
CHL1	 antibody.	 Several	 fluorescein-labeled	 protein	 bands	 were	
observed	in	CHL1	transfectant	HEK293	cells	but	not	in	mock	cells	
(Figure	3F,	middle	panel).	The	immunoprecipitation	experiment	after	
EMARS	reaction	(Figure	3F,	right	panel)	revealed	that	although	faint	
band	could	be	observed	in	IP	sample	from	mock	cells	(maybe	due	to	
nonspecific	binding	to	Sepharose	resin),	a	clear	band	was	observed	
in	that	from	CHL1	transfectant	cells.	It	was	found	that	exogenously	
transfected	CHL1	specifically	interacts	with	endogenous	α2 integrin 
in HEK293 cells.
3.3 | Localization of BiCAT in cancer cell membrane
We	 next	 examined	 whether	 the	 identified	 BiCATs	 co–expressed	
in the cell membrane. Confocal microscopy showed that α2 inte‐
grin	 (Figure	 S3A),	 β1	 integrin	 (Figure	 S3B),	 clusterin	 (Figure	 S3C),	
Na/K	 ATPase	 (Figure	 S3D),	 FGFR3	 (Figure	 S3E)	 and	 contactin1	
(Figure	S3F)	co–expressed	with	CHL1,	demonstrating	that	CHL1	and	
these	partner	molecules	formed	BiCAT	with	each	other	under	an	op‐
tical	microscope.	Electron	microscopy	using	LK2	cells	(Figure	4A-C)	
demonstrated	that	high	levels	of	gold	colloid	signals	of	CHL1	(10	nm	
particles)	and	partner	molecules	(5	nm	particles)	were	in	proximity	
on the cell membrane. The proteins were located relatively close to 
each other, with an interval of approximately 10‐50 nm. Moreover, 
many 5 and 10‐nm particles were observed in cellular vesicles 
(Figure	 4A-C),	 demonstrating	 that	 BiCAT	 existed	 not	 only	 in	 cell	
membranes but also in vesicular membranes.
3.4 | BiCAT in pathological specimens from lung 
cancer patients
Histopathological specimens derived from 55 mongoloid cases of 
lung	cancer	patients	were	stained	with	antibodies	against	CHL1	and	
α2	integrin	for	the	simple	detection	of	representative	CHL1	BiCAT	
identified	 by	 our	 experiments.	We	 first	 performed	 analysis	 under	
low	 magnification	 (×5	 objective)	 to	 detect	 co–expression	 signals	
between	 CHL1	 and	 α2	 integrin.	 CHL1	 and	 the	 partner	molecules	
were independently expressed in most tissues among 55 cases of 
lung cancer patients but did not show the same expression patterns 
among	patients	(Figure	S4).	Both	whole	and	local	expressions	in	the	
sections	were	observed.	Representative	imaging	of	CHL1	and	α2 in‐
tegrin	expression	is	shown	in	Figure	5A.	Some	tumor	specimens	had	
clear	or	moderate	co–expression	signals	of	CHL1-α2 integrin in the 
specific areas where cancer cells might be densely packed. The co–
expression area of each tumor specimen was then observed under 
high	magnification	 (×20	objective)	 and	 clear	 co–expression	 signals	
as	BiCAT	were	 found	 in	 specific	 cancer	 cells.	Next,	we	quantified	
the	co–expression	area	as	described	in	the	Supporting	Materials	and	
Methods	(Appendix	S1).	By	comparison	between	tumor	(Figure	5B)	
and	normal	 (Figure	5C)	 tissue	 slices	 in	each	 staining,	 it	was	 found	
that	 tumor	 slices	were	 significantly	 higher	 values	 for	CHL1-α2 in‐
tegrin staining compared with normal slices (4.827 ± 1.562 vs 
1.123 ± 0.709; P < 1 × 10−7;	Figure	5D).
3.5 | In vitro simulation of effective drug 
combination used for multiple drug treatment 
strategy based on BiCAT information
Using	BiCAT	 information,	we	tried	a	new	approach,	which	was	 in‐
tended for the improvement of multiple drug therapy,38 involving 
cancer cell proliferation inhibition by multiple antibody/inhibitor ad‐
ministration	(anti–CHL1	antibody,	FGFR3	inhibitor	and	α2β1 integrin 
inhibitor)	 against	 the	molecules	 constituting	BiCAT.	We	compared	
the efficacy between single and double administration of these an‐
tibody/inhibitors under 3 administration protocols (every day, once 
daily	and	every-other-day	protocols;	Figures	6A,	S5A	and	S5B).	For	
efficient evaluation of the effects of double administration, the con‐
centration of each agent was set to the appropriate concentration 
(data	 not	 shown).	 Statistical	 analyses	 were	 performed	 using	 both	
Tukey's test and Dunnett's multiple test (Figure 6B; Dunnett's multi‐
ple	test).	The	results	of	Tukey's	analysis	are	summarized	in	Table	S7.
As	shown	in	Figure	S5A,	double	administration	(CHL1	+	PD173074,	
CHL1	+	BTT3033	or	PD173074	+	BTT3033)	was	moderately	effec‐
tive	 (approximately	 30%	 average	 inhibition),	 in	 contrast	 to	 single	
administration	(approximately	10%	average	inhibition)	for	LK2	cells	
at	Day	2.	Otherwise,	double	administration	(PD173074	+	BTT3033)	
was only statistically significant for EML4‐ALK primary cells at Day 
2. The efficacy of double administration at Day 5 seemed to have 
greater variation or was weaker than that at Day 2 in both cell types. 
In daily treatments, as shown in Figure 6B, double administration was 
similarly effective as single treatments, in contrast to no statistically 
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F I G U R E  4  BiCAT	located	in	lung	cancer	cell	membranes	and	cellular	vesicles.	A-C,	Morphological	observation	of	BiCAT	in	LK2	cells	using	
electron	microscopy.	Cultured	LK2	cells	were	fixed	and	co–stained	with	CHL1	(indicated	as	10	nm	particles)	and	partner	molecules	identified	
in cell membrane. α2	integrin	(A),	FGFR3	(B)	and	contactin1	(C)	were	indicated	as	5	nm	particles.	Arrows	indicate	the	locations	of	gold	
particles.	Scale	bar:	100-500	nm
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significant	inhibition	after	single	administration	for	LK2	cells	at	Day	
2. EML4‐ALK primary cells at Day 2 showed similar results as cells 
treated with the single treatment. On Day 4, the double administra‐
tion	was	clearly	effective	for	LK2	cells	(approximately	50%	average	
inhibition)	and	moderately	effective	for	EML4‐ALK primary cells (ap‐
proximately	30%	average	 inhibition).	 In	 the	 every-other-day	 treat‐
ment	condition	(Figure	S5B),	double	administration	was	slightly	less	
effective than the daily treatment protocol at Day 1 and Day 3 for 
LK2	cells,	except	 for	PD173074	+	BTT3033	 treatment.	For	EML4‐
ALK primary cells, double administration showed similar results as 
those with the daily treatment protocol at Day 1; however, there was 
significant efficacy in both single and double administration at Day 
3.	In	contrast	to	these	experiments	based	on	BiCAT	information,	the	
cell	 proliferation	 assay	 using	 ALK	 inhibitors	 (CH5424802)	 against	
F I G U R E  5  BiCAT	located	in	the	pathological	specimens	from	lung	cancer	patients.	A,	Representative	images	of	CHL1-α2	integrin	BiCAT-
positive	specimens	from	55	cases	of	lung	cancer	patients.	The	lung	cancer	specimens	were	co–stained	with	anti–CHL1	antibody	(red)	and	
anti–α2	integrin	antibody	(green),	respectively.	DAPI	solution	was	used	for	the	nuclear	DNA	staining.	Then,	the	resulting	specimens	were	
observed	with	confocal	microscopy	(×5	objective).	Both	tumor	tissues	(upper	panel)	and	normal	tissue	(middle	panel)	were	stained	under	
the	same	conditions.	Representative	images	at	high	magnification	observation	(×20	objective;	lower	panel)	in	part	of	the	positive	region	of	
BiCAT	indicated	as	the	merged	area	(yellow).	B,	C,	Quantitative	analysis	of	co–expression	signals	of	CHL1-α2	integrin	BiCAT	molecule.	The	
co–expression	area	was	quantified	using	Image	J	software	as	described	in	the	Supporting	Materials	and	Methods	(Appendix	S1).	B,	Tumor	
slices.	C,	Normal	slices.	The	quantitative	values	of	the	co–expression	signals	are	shown	in	mean	gray	value.	D,	Statistical	analysis	of	mean	
gray	value	of	CHL1-α2	integrin	BiCAT	between	normal	and	tumor	tissues.	The	analysis	was	performed	with	the	Mann–Whitney	test	using	R	
software	and	EZR.	P < 1 × 10−7.	The	CHL1-α2	integrin	BiCAT	had	significantly	higher	expression	in	tumor	tissues
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F I G U R E  6   In	vitro	simulation	of	effective	drug	combination	to	inhibit	cancer	cell	proliferation	based	on	BiCAT	information.	A,	The	single	
and	double	administration	under	daily	treatment	protocol	(n	=	5).	The	administration	timing	is	indicated	by	closed	triangles.	The	cell	numbers	
of	the	treated	cells	were	measured	on	Day	2	and	Day	4.	B,	The	relative	ratio	(%	of	non–treated	cells	as	control)	of	cell	proliferation	rates	in	
LK2	cells	and	EML4‐ALK primary cells. The statistical analysis was performed using Tukey's test and Dunnett's multiple test. The results from 
Dunnett's test are presented in Figure 6; *P < 0.05; **P < 0.005; ***P < 0.001. C, Double administration of molecular targeted reagents leads 
to	changes	in	the	expression	of	partner	molecules.	The	samples	of	single	and	double	administration	under	daily	treatment	conditions	(3	d)	
in	LK2	cells	were	subjected	to	phos-tag	SDS-PAGE	and	then	western	blot	analysis	using	CHL1,	α2 integrin and FGFR3 antibodies. The CBB 
staining	image	indicates	load	control.	The	molecular	weight	markers	were	not	shown	in	this	figure	because	phos-tag	SDS-PAGE	cannot	show	
the	correct	molecular	weight	of	sample	proteins.	D,	Western	blot	analysis	of	phosphorylated	FGFR3	in	single	and	double	administration	
samples.	The	samples	under	daily	treatment	conditions	(3	d)	in	LK2	cells	were	subjected	to	normal	SDS-PAGE	gel	and	then	western	blot	
analysis	using	anti–FGFR3	and	anti–phospho-FGFR3	antibodies.	The	quantification	of	the	phosphorylated	bands	detected	in	FGFR3	blots	
was	performed	using	Image	J	software	(ver.	1.51).	The	ratio	of	phosphorylation	among	the	samples	is	indicated	below	the	figure.	E,	Western	
blot	analysis	of	phospho-focal	adhesion	kinase	(FAK)	in	single	and	double	administration	samples.	The	samples	under	daily	treatment	
conditions	(3	d)	in	LK2	cells	were	subjected	to	normal	SDS-PAGE	and	then	western	blot	analysis	using	anti–FAK	and	anti–phospho-FAK	
antibodies
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EML4‐ALK primary cells showed approximately 10%‐30% inhibition 
at	Day	2	and	Day	4	(Figure	S6).
These experiments under 3 protocols indicated that while the 
degree of inhibitory ratio differed among the protocols, we observed 
not only an additive effect but also a synergistic effect for the re‐
agents	against	BiCAT	molecules.	For	instance,	the	synergistic	inhibi‐
tory effects of around 30% were observed at Day 2 with the double 
administration	of	3	reagents	in	LK2	cells	(Figure	6B	“LK2‐Day 2”).
To	 assess	 the	 importance	 of	 proximity	 of	 BiCAT	 molecules	
(FGFR3‐α2	 integrin)	 for	 cell	 proliferation	 inhibition	 in	 cancer	 cells,	
several	(IgG)2 antibodies
31‐33	(Figure	S7A),	similar	products	to	bispe‐
cific	antibodies,	were	 treated	with	LK2	cells.	The	binding	capacity	
of	 each	 (IgG)2 antibody was examined using fluorescence micros‐
copy. The patched staining was observed in each sample, suggesting 
that	 Ab	mix	 1-3	 contained	 (IgG)2 antibodies that induced an anti‐
gen	crosslinking	on	 the	LK2	cell	 surface	 (Figure	S7B).	The	Ab	mix	
1	seemed	to	bind	most	strongly	to	LK2	cells,	followed	by	Ab	mix	3	
containing FGFR3‐α2	integrin-(IgG)2	antibody.	Although	all	Ab	mixes	
showed the tendency to inhibit proliferation on Day 4, the treated 
LK2	cells	with	Ab	mix	3,	which	theoretically	contains	FGFR3-α2 in‐
tegrin-(IgG)2	antibody	and	only	one-third	of	whole	(IgG)2 antibodies, 
and	Ab	mix	4	showed	statistically	significant	proliferation	inhibition	
(Figure	S7C).
To examine the influence of double treatment, we performed 
western	blot	analysis	on	 the	 reagent	 treated-cells.	The	UniProtKB	
database	 indicated	 that	 human	 and	mouse	CHL1,	α2 integrin and 
FGFR3	are	phosphorylated	proteins	 (data	not	shown).	Using	Phos-
tag	gel,	CHL1	was	detected	as	2	bands,	which	may	reflect	the	differ‐
ences	in	phosphorylation	of	CHL1	(Figure	6C	“CHL1”).	However,	the	
lower band was only detected in the control sample, so that it is un‐
clear whether double administration affects the phosphorylation in 
CHL1.	In	contrast,	the	upper	bands	were	clearly	reduced	in	only	dou‐
ble	administration	samples	(CHL1	+	PD173074,	CHL1	+	BTT3033	or	
PD173074	+	BTT3033)	compared	with	the	control	and	other	single	
administration	samples,	despite	equal	amounts	of	 loaded	samples.	
As	with	CHL1,	FGFR3	was	detected	as	2	bands	and	was	reduced	in	
both	CHL1	+	BTT3033	and	PD173074	+	BTT3033	double	adminis‐
tration	samples	(Figure	6C	“FGFR3”).	To	confirm	whether	phosphor‐
ylation in these molecules is changed by double administration, the 
western	blot	analysis	using	normal	SDS-PAGE	gel	was	performed	and	
stained with anti–phospho antibody. The slight alterations of phos‐
phorylation in FGFR3 were observed in double administration sam‐
ples	(CHL	1	+	PD	173074,	CHL	1	+	BTT	3033	or	PD	173074	+	BTT	
3033)	(Figure	6D).	Unfortunately,	in	the	case	of	CHL1,	the	bands	of	
phosphorylated	CHL1	could	not	be	detected	in	all	samples	by	using	
normal	SDS-PAGE	gel	(data	not	shown).	Although	some	changes	of	
phosphorylation in FGFR3 were detected in double administration 
samples, the contribution of phosphorylation was unclear because it 
was not a critical change. α2 integrin in the samples with double ad‐
ministration was reduced, whereas there was no significant gel shift 
of α2 integrin in the double administration samples (Figure 6C “α2 in‐
tegrin”).	To	investigate	whether	total	integrin	functions	are	affected	
by double administration, we observed phosphorylation of focal 
adhesion	kinase	(FAK),	which	is	the	downstream	signal	molecule	of	
integrin39 using western blot analysis. The decrease of phosphor‐
ylation	of	 FAK	was	observed	 in	 the	 double	 administration	 sample	
(Figure	6E).
4  | DISCUSSION
Here,	we	examined	whether	a	BiCAT	is	useful	as	a	novel	cancer	tar‐
get for molecular targeted strategies in terms of improving specific‐
ity by designation of 2 or more molecules compared to 1 molecule 
antigen.40
The	 EMARS	method	 that	we	 previously	 developed14 could be 
suitable	 for	clarifying	BiCAT	 in	primary	cancer	cells	under	physio‐
logical	 conditions.	We	 selected	EML4‐ALK transgenic mice for the 
study as the primary culture cells can be relatively easily established 
from the lung cancer tumor tissue derived from these mice. The es‐
tablishment of primary culture cells from human cancer tissues has 
been reported.41 If primary culture cells can similarly be developed 
from	human	cancer	biopsy	 tissue,	BiCAT	could	possibly	be	 simply	
identified	 using	 the	 EMARS	method	 for	 each	 patient,	 resulting	 in	
personalized cancer medicine. Furthermore, the primary cancer cells 
are important for the in vitro simulation of medicine selection de‐
scribed in Figure 6.
Considering high expression and high specificity cancer antigen 
is	typically	required,	the	selected	target	molecule	for	EMARS	probe	
was preferable to be high expression and specificity in cancer tis‐
sue. It is, therefore, necessary to perform preliminary experiments 
(eg,	cDNA	microarray)	or	pre–assessment	for	the	determination	of	
appropriate molecules. In the EML4‐ALK	transgenic	mouse,	CHL1	ex‐
pression was restricted to the cancer tissue without any correlations 
to	age	and	sex	(Figure	2B),	suggesting	that	CHL1	is	a	good	candidate	
target	molecule.	CHL1	is	a	cell	adhesion	molecule	and	has	been	re‐
ported to be involved in several neuronal functions (eg, neurite out‐
growth and dendrite orientation in the cerebellar and hippocampal 
neurons).42,43 However, it should be taken into consideration that 
partner	molecules	 that	 form	BiCAT	with	CHL1	are	highly	 likely	 to	
form	BiCAT	with	each	other.	In	this	study,	we	may	also	have	to	con‐
sider the combinations among FGFR3, α2 integrin and contactin1.
In	the	proteomics	analysis	of	EMARS	products	with	mass	spec‐
trometry, there was no overlap of listed candidate molecules be‐
tween EML4‐ALK	 primary	 cells	 and	LK2	cells	 (Table	S2),	 indicating	
that	 the	 partner	 molecules	 constituting	 BiCAT	 with	 CHL1	 were	
different among cancer cell types or species. However, we hypoth‐
esized that the partner molecule information obtained from EML4‐
ALK	primary	cells	was	applicable	to	LK2	cells	and	vice	versa	because	
it is sometimes insufficient to analyze due to differences in the ion‐
ization	efficiency	of	molecules	 in	mass	spectrometry.	Using	cDNA	
microarray data, we also examined the changes of expression levels 
of representative partner molecules identified above. There was no 
significant	change	(data	not	shown),	indicating	that	BiCAT	formation	
was not simply dependent on the overexpression of both constitu‐
ent molecules that occurs in cancer.
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The immunostaining experiment of lung cancer tissues derived 
from lung cancer patients provides crucial information for the clini‐
cal	application	of	BiCAT.	Using	quantitative	analysis,	we	found	that	
CHL1-α2	 integrin	 BiCAT	may	 be	 expressed	 in	 human	 lung	 cancer	
tumor	tissue,	and	almost	all	tumor	slices	(92.7%)	became	“positive”	
for	CHL1-α2	integrin	staining	compared	to	the	quantitative	data	in	
normal tissues. In lung cancer treatment, epithelial growth factor re‐
ceptor	(EGFR),	 including	its	mutant	form,	and	EML4‐ALK are highly 
expressed, and are well‐known targets for molecular targeted lung 
cancer drugs such as gefitinib,44,45 cetuximab46 and crizotinib.47	A	
previous study reported that EGFR is overexpressed in 40%‐80% of 
non–small cell lung cancer patients,48 and EGFR mutations have also 
been detected in 19.4% of lung cancer patients.49 The EML4–ALK 
fusion gene was detected in 6.7% of non–small cell lung cancer pa‐
tients.34	The	expression	property	of	CHL1-α2	integrin	BiCAT	on	the	
slices is thought to be as good as for typical antigens.
As	a	new	approach	to	molecular	targeted	strategy,	we	attempted	to	
perform a simulation of effective drug combinations for multiple drug 
administration38	 that	 inhibit	cancer	cell	proliferation	based	on	BiCAT	
information. This is based on previous findings that molecular com‐
plexes are important for signal transduction involved in cell functions 
through affecting other signals.50	For	instance,	CHL1	and	integrins	co‐
operatively contribute to signal transduction by interacting with each 
other.51‐53 Considering this concept, a bispecific antibody may be the 
best	tool	to	discuss	whether	the	proximity	(interaction)	among	BiCAT	
molecules is important for cancer cell proliferation inhibition. In this 
study,	we	used	(IgG)2 antibodies
31‐33 for the assay because they can be 
generated	in	less	time	than	bispecific	antibodies.	The	(IgG)2 antibodies 
containing FGFR3‐α2	 integrin-(IgG)2 antibody significantly inhibited 
cell	proliferation	in	LK2	cells	 (Figure	S7),	suggesting	that	the	proxim‐
ity	 (interaction)	 among	BiCAT	molecules	 is	 also	 an	 important	 factor.	
However, the effect was also observed in the double administration of 
single FGFR3 and α2 integrin antibodies, similar to the double adminis‐
tration experiments described in Figure 6B, suggesting that similar cell 
proliferation inhibition is possibly induced by single antibody combina‐
tion treatment other than bispecific antibody treatment.
Although	our	results	could	not	completely	demonstrate	whether	
bimolecular	 interactions	 in	BiCAT	contribute	to	the	synergistic	ac‐
tion	 of	 each	 reagent,	 BiCAT	 information	 has	 the	 potential	 to	 help	
inform drug selection for multiple drug therapy with synergic ef‐
fects. The efficacies of double administration in this study were not 
very powerful (especially for EML4‐ALK	primary	cells),	and,	thus,	 it	
seems	necessary	to	improve	on	the	selection	of	appropriate	BiCAT	
in further studies. The molecular mechanism of this synergistic inhi‐
bition	based	on	BiCAT	information	has	never	been	clearly	identified;	
however,	our	results	suggest	that	the	decreased	expression	of	BiCAT	
molecules induced by double administration may contribute to syn‐
ergic inhibition. In the phosphorylation, significant phosphorylation 
change was not clearly observed in double administration samples 
(Figure	 6C,D),	 suggesting	 that	 the	 phosphorylation	 change	 in	 the	
BiCAT	molecule	 itself	may	 be	 a	 partial	 but	 not	 a	 critical	 factor	 of	
proliferation inhibition. Because each agent inhibits the phosphor‐
ylation of the target molecule itself like many molecular targeted 
medicines, the mechanism of the cell proliferation inhibitory effect 
by	BiCAT-dependent	double	administration	is	of	interest.	Regarding	
the	decrease	 in	 the	expression	of	BiCAT	molecules,	 there	 is	 some	
contribution to the synergic inhibition, but it is unknown how dou‐
ble administration induces the decrease in the expression of each 
BiCAT	molecule.	In	contrast,	the	double	administration	induced	the	
decrease	of	FAK	signaling	in	the	downstream	of	integrin	(Figure	6E),	
indicating	that	the	regulation	of	BiCAT	molecules	by	drug	treatment	
affects	not	only	the	expression	of	BiCAT	molecules	themselves	but	
also the overall signal transductions and cellular functions.
Moreover,	 it	 would	 be	 interesting	 if	 BiCAT	 information	 could	
contribute to the development of antibody medicine32,54 in rec‐
ognizing	 cancer-specific	 BiCA	 for	 cancer	 treatment.	 In	 fact,	 strat‐
egies with antibodies recognizing 2 cell membrane molecules have 
already been developed as molecular targeted bispecific antibody 
medicine for cancer treatment.32,54	Among	them,	the	bispecific	an‐
tibodies recognizing cis‐bimolecules	similar	to	BiCAT	have	only	been	
reported in a few cases (EGFR‐IGFR,55 EGFR‐Met,56 CD20‐CD2257).	
These anticancer targets are well known and predictable. In our 
strategy, because of direct identification of proximity molecules on 
cell membrane, it is an advantage to find not only bimolecules that 
are predictable based on past findings, but also completely unknown 
bimolecules that are impossible to predict.
In	 conclusion,	 BiCAT	 have	 specific	 features	 and	 advantages	 in	
terms of the possibility of the development of novel targets and the 
improvement of antigen specificity not present in typical cancer 
targets, and may contribute to the discovery of effective and novel 
molecular targets.
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